L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 15:50:01 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 88 TO ITERATE

100.0% PROCESSED 88 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1198 TO 2322
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 15:50:06 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1687 TO ITERATE

100.0% PROCESSED 1687 ITERATIONS 30 ANSWERS
SEARCH TIME: 00.00.01

L3 30 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 178.36 178.57

FILE 'CAPLUS' ENTERED AT 15:50:14 ON 22 SEP 2008

FILE COVERS 1907 - 22 Sep 2008 VOL 149 ISS 13
FILE LAST UPDATED: 21 Sep 2008 (20080921/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l3
L4 2 L3

=> d abs fbib hitstr 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a preparation of novel pyrazolo[4,3-c]quinoline derivs. of formula I [wherein: Z is carboxylic acid or ester group; X is a bond or a divalent group selected from alkylene, or NHC(O), etc.; Y is O, S, N-oxide, or NH, etc.; R1 and R3 are independently selected from H, F, Cl, NO2, or CN, etc.; R2 (un)substituted C3-7cycloalkyl or phenyl] as immunomodulatory agents, useful for the treatment of rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythamatosis, and psoriasis. The title compds. are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28. For instance, IC50 for the prepared pyrazoloquinoline derivative II was 3.4 μM

(example 7).
AN 2004:534202 CAPLUS
DN 141:71540
TI A preparation of pyrazolo[4,3-c]quinoline derivatives, useful as immunomodulatory agents
IN Matthews, Ian Richard; Huxley, Philip; Magaraci, Filippo; Brennan, Chris James; Uddin, Muhammed Kamal; Pettersson, Lars Olof Goeran; Thrige, Dorthe Da Graca
PA Active Biotech Ab, Swed.
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004055014	A1	20040701	WO 2003-SE1941	20031212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			SE 2002-3722	A 20021216
			US 2002-433580P	P 20021216
AU 2003287129	A1	20040709	AU 2003-287129	20031212
			SE 2002-3722	A 20021216
			US 2002-433580P	P 20021216
			WO 2003-SE1941	W 20031212
EP 1572689	A1	20050914	EP 2003-781198	20031212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
			SE 2002-3722	A 20021216
			US 2002-433580P	P 20021216
			WO 2003-SE1941	W 20031212
US 20060035919	A1	20060216	US 2005-537538	20050915
			SE 2002-3722	A 20021216
			US 2002-433580P	P 20021216
			WO 2003-SE1941	W 20031212

OS MARPAT 141:71540
IT 713141-32-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazoloquinoline derivs. useful as immunomodulatory agents)
RN 713141-32-3 CAPLUS
CN Benzoic acid, 4-[3,5-dihydro-4-(4-nitrophenyl)-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl]-, methyl ester (CA INDEX NAME)



IT 713141-33-4P 713141-34-5P 713141-35-6P
713141-36-7P 713141-37-8P 713141-38-9P
713141-39-0P 713141-40-3P 713141-41-4P
713141-42-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazoloquinoline derivs. useful as immunomodulatory agents)

RN 713141-33-4 CAPLUS
CN Benzoic acid, 4-[4-(4-aminophenyl)-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl]-, methyl ester (CA INDEX NAME)



RN 713141-34-5 CAPLUS
CN Benzoic acid, 4-[3,5-dihydro-4-(4-nitrophenyl)-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl]- (CA INDEX NAME)



RN 713141-35-6 CAPLUS
CN Benzoic acid, 3-[3,5-dihydro-4-(4-nitrophenyl)-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl]- (CA INDEX NAME)



RN 713141-36-7 CAPLUS
CN Benzoic acid, 4-[3,5-dihydro-4-(3-nitrophenyl)-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl]- (CA INDEX NAME)



RN 713141-37-8 CAPLUS
CN Benzoic acid, 4-[3,5-dihydro-4-(4-methoxyphenyl)-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl]-, methyl ester (CA INDEX NAME)



RN 713141-38-9 CAPLUS
CN Benzoic acid, 4-[3,5-dihydro-4-(4-methoxyphenyl)-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl]- (CA INDEX NAME)



RN 713141-39-0 CAPLUS
CN Benzoic acid, 4-[4-(4-aminophenyl)-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl]- (CA INDEX NAME)



RN 713141-40-3 CAPLUS
CN Benzoic acid, 3-[3,5-dihydro-4-(4-methoxyphenyl)-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl]- (CA INDEX NAME)



RN 713141-41-4 CAPLUS
CN Benzoic acid, 4-[3,5-dihydro-4-(3-nitrophenyl)-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl]-, methyl ester (CA INDEX NAME)



RN 713141-42-5 CAPLUS
CN Benzoic acid, 4-[3,5-dihydro-3-oxo-4-(2,4,5-trifluorophenyl)-2H-pyrazolo[4,3-c]quinolin-2-yl]- (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to novel heterocyclic compds., to methods for their preparation, to compns. containing them, and to methods and use for clin. treatment of medical conditions which may benefit from immunomodulation, including rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis, and psoriasis. More particularly, the invention relates to novel heterocyclic compds. I, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28. In formula I, R1 and R3 independently represent H, F, Cl, Br, NO2, CN, C1-C6 alkyl optionally substituted by F or Cl, or C1-C6 alkoxy optionally substituted by F; R2 represents H, or optionally substituted C1-C6 alkyl, C3-C7 cycloalkyl, or optionally substituted Ph; Y represents O, S, N-oxide, or N(R5), wherein R5 represents H or C1-C6 alkyl; X represents a bond or a divalent C1-C6 alkylene radical; R4 represents -C(O)NR6R7, -NR7C(O)R6, -NR7C(O)OR6, -NHC(O)NHR6, or -NHC(S)NHR6, wherein R6 represents H, or a radical of formula -(Alk)b-Q wherein b = 0-1 and Alk is an optionally substituted divalent straight chain or branched C1-C12 alkylene, C2-C12 alkenylene or C2-C12 alkynylene radical which may be interrupted by one or more non-adjacent -O-, -S- or -N(R8)- radicals wherein R8 represents H or C1-C4 alkyl, C3-C4 alkenyl, C3-C4 alkynyl, or C3-C6 cycloalkyl, and Q represents H, CF3, OH, SH, NR8R8 wherein each R8 may be the same or different, an ester group, or an optionally substituted Ph, C3-C7 cycloalkyl, C5-C7 cycloalkenyl or heterocyclic ring having from 5 to 8 ring atoms; and R7 represents H or C1-C6 alkyl; or when taken

together with the atom or atoms to which they are attached, R6 and R7 form an optionally substituted heterocyclic ring having from 5 to 8 ring atoms. Approx. 170 example compds. and several intermediates were prepared For instance, invention compound II (claimed individually) was prepared in 5 steps: (1) cyclocondensation of 3-cyclopropyl-3-oxopropionic acid Me ester with Et 2-aminobenzoate to give a quinolone derivative, (2) conversion of the quinolone ester to a chloroquinoline ester with POCl3, (3) cyclocondensation of the latter with 4-hydrazinobenzoic acid to form the pyrazole ring, (4) conversion of the free acid group to an acid chloride, and (5) amidation with H2N(CH2)3NMe2. In a cell-free, Eu/APC-based, homogeneous time-resolved fluorescence (HTRF) assay, used to determine inhibition of CD80-CD28 interaction, II had EC50 < 1 μM.

AN 2004:467892 CAPLUS
DN 141:38606
TI Pyrazoloquinolines and analogs with CD80 antagonist immunomodulating activity, and their preparation, pharmaceutical compositions, and use
IN Matthews, Ian Richard; Coulter, Thomas Stephen; Ghiron, Chiara; Brennan, Chris James; Uddin, Muhammed Kamal; Pettersson, Lars Olof Goeran; Da Graca Thrige, Dorthe; Huxley, Philip
PA Active Biotech AB, Swed.
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2004048378	A1	20040610	WO 2003-SE1805		20031121
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				SE 2002-3471	A	20021122
				US 2002-428240P	P	20021122
				SE 2003-1299	A	20030506
				SE 2003-1851	A	20030625
				US 2003-482122P	P	20030625
	CA 2506524	A1	20040610	CA 2003-2506524		20031121
				SE 2002-3471	A	20021122
				US 2002-428240P	P	20021122
				SE 2003-1299	A	20030506
				SE 2003-1851	A	20030625
				US 2003-482122P	P	20030625
				WO 2003-SE1805	W	20031121
	US 20040116461	A1	20040617	US 2003-717519		20031121
	US 20050203118	A9	20050915			
	US 7081456	B2	20060725			
				SE 2002-3471	A	20021122
				US 2002-428240P	P	20021122
				SE 2003-1299	A	20030506

				SE 2003-1851	A	20030625
				US 2003-482122P	P	20030625
AU 2003279687	A1	20040618		AU 2003-279687		20031121
				SE 2002-3471	A	20021122
				US 2002-428240P	P	20021122
				SE 2003-1299	A	20030506
				SE 2003-1851	A	20030625
				US 2003-482122P	P	20030625
				WO 2003-SE1805	W	20031121
EP 1562944	A1	20050817		EP 2003-773026		20031121
EP 1562944	B1	20070214				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK						
				SE 2002-3471	A	20021122
				US 2002-428240P	P	20021122
				SE 2003-1299	A	20030506
				SE 2003-1851	A	20030625
				US 2003-482122P	P	20030625
				WO 2003-SE1805	W	20031121
JP 2006509047	T	20060316		JP 2005-510306		20031121
				SE 2002-3471	A	20021122
				US 2002-428240P	P	20021122
				SE 2003-1299	A	20030506
				SE 2003-1851	A	20030625
				US 2003-482122P	P	20030625
				WO 2003-SE1805	W	20031121
ZA 2005003968	A	20060927		ZA 2005-3968		20031121
				SE 2002-3471	A	20021122
AT 353898	T	20070315		AT 2003-773026		20031121
				SE 2002-3471	A	20021122
				US 2002-428240P	P	20021122
				SE 2003-1299	A	20030506
				SE 2003-1851	A	20030625
				US 2003-482122P	P	20030625
EP 1813616	A2	20070801		EP 2007-102257		20031121
EP 1813616	A3	20070808				
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR, AL, LT, LV, MK						
				SE 2002-3471	A	20021122
				US 2002-428240P	P	20021122
				SE 2003-1299	A	20030506
				SE 2003-1851	A	20030625
				US 2003-482122P	P	20030625
				EP 2003-773026	A3	20031121
ES 2282693	T3	20071016		ES 2003-773026		20031121
				SE 2002-3471	A	20021122
				US 2002-428240P	P	20021122
				SE 2003-1299	A	20030506
				SE 2003-1851	A	20030625
NZ 540081	A	20080328		NZ 2003-540081		20031121
				SE 2002-3471	A	20021122
				US 2002-428240P	P	20021122
				SE 2003-1299	A	20030506
				SE 2003-1851	A	20030625
				US 2003-482122P	P	20030625
				WO 2003-SE1805	W	20031121

RU 2328496	C2	20080710	RU 2005-119639		20031121
			SE 2002-3471	A	20021122
			US 2002-428240P	P	20021122
			SE 2003-1299	A	20030506
			SE 2003-1851	A	20030625
			US 2003-482122P	P	20030625
			WO 2003-SE1805	W	20031121
IN 2005CN00959	A	20070810	IN 2005-CN959		20050517
			SE 2002-3471	A	20021122
			WO 2003-SE1805	W	20031121
NO 2005003018	A	20050822	NO 2005-3018		20050620
			SE 2002-3471	A	20021122
			US 2002-428240P	P	20021122
			SE 2003-1299	A	20030506
			SE 2003-1851	A	20030625
			US 2003-482122P	P	20030625
			WO 2003-SE1805	W	20031121
US 20060217411	A1	20060928	US 2006-442548		20060530
US 7291612	B2	20071106			
			SE 2002-3471	A	20021122
			US 2002-428240P	P	20021122
			SE 2003-1299	A	20030506
			SE 2003-1851	A	20030625
			US 2003-482122P	P	20030625
			US 2003-717519	A3	20031121
HK 1086562	A1	20080328	HK 2006-106518		20060607
			SE 2002-3471	A	20021122
			US 2002-428240P	P	20021122
			SE 2003-1299	A	20030506
			SE 2003-1851	A	20030625
			US 2003-482122P	P	20030625
			WO 2003-SE1805	W	20031121

OS MARPAT 141:38606

IT 702704-93-6P, N-(3-Dimethylaminopropyl)-4-(4-cyclopropyl-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-30-4P, N-[4-(Pyrrolidin-1-yl)butyl]-4-(4-cyclopropyl-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-51-9P, N-(1-Benzyl-4-piperidinyl)-4-(4-cyclopropyl-6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-52-0P, N-(1,2,2,6,6-Pentamethylpiperidin-4-yl)-4-(4-cyclopropyl-6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-55-3P, N-(1,2,2,6,6-Pentamethylpiperidin-4-yl)-4-(4-cyclopropyl-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-56-4P, N-[4-(Pyrrolidin-1-yl)butyl]-4-(4-cyclopropyl-6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-58-6P, N-[3-(Dimethylamino)propyl]-4-(4-cyclopropyl-6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-59-7P, N-(2,2,6,6-Tetramethylpiperidin-4-yl)-4-(4-cyclopropyl-6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-60-0P, endo-N-(8-Methyl-8-azabicyclo[3.2.1]oct-3-yl)-4-(4-cyclopropyl-6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-61-1P , N-[4-(Diethylamino)butyl]-4-(4-cyclopropyl-6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-62-2P, N-[1-(tert-Butoxycarbonyl)piperidin-4-yl]-4-(4-cyclopropyl-6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-63-3P, N-[3-[4-[(2-Chloro-6-fluorophenyl)methyl]piperazin-1-yl]propyl]-4-(4-

cyclopropyl-6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-64-4P, N-[2-(Pyridin-2-yl)ethyl]-4-(4-cyclopropyl-6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-65-5P, N-[2-(Pyridin-3-yl)ethyl]-4-(4-cyclopropyl-6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-66-6P, N-[2,2-Dimethyl-3-(dimethylamino)propyl]-4-(4-cyclopropyl-6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-67-7P, N-[3-(Pyrrolidin-1-yl)propyl]-4-(4-cyclopropyl-6-fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzamide 702705-78-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrazoloquinolines and analogs as CD80 antagonists and immunomodulators)

RN 702704-93-6 CAPLUS
CN Benzamide, 4-(4-cyclopropyl-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[3-(dimethylamino)propyl]- (CA INDEX NAME)



RN 702705-30-4 CAPLUS
CN Benzamide, 4-(4-cyclopropyl-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[4-(1-pyrrolidinyl)butyl]- (CA INDEX NAME)



RN 702705-51-9 CAPLUS
CN Benzamide, 4-(4-cyclopropyl-6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)



RN 702705-52-0 CAPLUS
CN Benzamide, 4-(4-cyclopropyl-6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-(1,2,2,6,6-pentamethyl-4-piperidinyl)- (CA INDEX NAME)



RN 702705-55-3 CAPLUS
CN Benzamide, 4-(4-cyclopropyl-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-(1,2,2,6,6-pentamethyl-4-piperidinyl)- (CA INDEX NAME)



RN 702705-56-4 CAPLUS
CN Benzamide, 4-(4-cyclopropyl-6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[4-(1-pyrrolidinyl)butyl]- (CA INDEX NAME)



RN 702705-58-6 CAPLUS
CN Benzamide, 4-(4-cyclopropyl-6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[3-(dimethylamino)propyl]- (CA INDEX NAME)



RN 702705-59-7 CAPLUS
CN Benzamide, 4-(4-cyclopropyl-6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (CA INDEX NAME)



RN 702705-60-0 CAPLUS
CN Benzamide, 4-(4-cyclopropyl-6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]- (CA INDEX NAME)

Relative stereochemistry.



RN 702705-61-1 CAPLUS
CN Benzamide, 4-(4-cyclopropyl-6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[4-(diethylamino)butyl]- (CA INDEX NAME)



RN 702705-62-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[4-(4-cyclopropyl-6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)benzoyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 702705-63-3 CAPLUS
CN Benzamide, N-[3-[4-[(2-chloro-6-fluorophenyl)methyl]-1-piperazinyl]propyl]-4-(4-cyclopropyl-6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-

yl)- (CA INDEX NAME)



RN 702705-64-4 CAPLUS
CN Benzamide, 4-(4-cyclopropyl-6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)



RN 702705-65-5 CAPLUS
CN Benzamide, 4-(4-cyclopropyl-6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[2-(3-pyridinyl)ethyl]- (CA INDEX NAME)



RN 702705-66-6 CAPLUS
CN Benzamide, 4-(4-cyclopropyl-6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[3-(dimethylamino)-2,2-dimethylpropyl]- (CA INDEX NAME)



RN 702705-67-7 CAPLUS
CN Benzamide, 4-(4-cyclopropyl-6-fluoro-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)-N-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 702705-78-0 CAPLUS
CN Carbamic acid, [4-(4-cyclopropyl-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)



IT 702706-05-6P, 4-(4-Cyclopropyl-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzoic acid 702706-06-7P, 4-(4-Cyclopropyl-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)benzoyl chloride
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyrazoloquinolines and analogs as CD80 antagonists and immunomodulators)
RN 702706-05-6 CAPLUS

CN Benzoic acid, 4-(4-cyclopropyl-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (CA INDEX NAME)



RN 702706-06-7 CAPLUS
CN Benzoyl chloride, 4-(4-cyclopropyl-3,5-dihydro-3-oxo-2H-pyrazolo[4,3-c]quinolin-2-yl)- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT